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Abstract 24 
There is keen research upon the effects of nutraceuticals on Inflammatory Bowel 25 
Disease. The purpose of this study was to explore the effect of Mastiha supplement, rich 26 
in bioactive nutraceuticals, in active Inflammatory Bowel Disease. This is a 27 
randomised, double-blind, placebo-controlled clinical trial. Α total of 60 Inflammatory 28 
Bowel Disease patients were enrolled and randomly allocated Mastiha (2.8g/day) or 29 
placebo groups for 3 months adjunct to stable medical treatment. Medical and dietary 30 
history, Inflammatory Bowel Disease Questionnaire, Harvey-Bradshaw Index, Partial 31 
Mayo Score, biochemical indices, faecal and blood inflammatory markers were 32 
assessed. A clinically important difference between groups in IBDQ was defined as 33 
primary outcome.  34 
Inflammatory Bowel Disease Questionnaire score significantly improved in verum 35 
compared with baseline (p=0.004). There was a significant decrease in faecal lysozyme 36 
in Mastiha patients (p=0.018) with the mean change being significant (p=0.021) and 37 
significant increases of faecal lactoferrin (p=0.001) and calprotectin (p=0.029) in the 38 
placebo group. Fibrinogen reduced significantly (p=0.006) with a significant mean 39 
change (p=0.018), whereas iron increased (p=0.032) in Mastiha arm.  40 
Our results show regulation of faecal lysozyme by Mastiha supplement adjunctive to 41 
pharmacological treatments in active inflammatory bowel disease. An effect secondary 42 
to a prebiotic potency is proposed.  43 
ClinicalTrials.gov Identifier: NCT02796339 44 
 45 
Keywords: nutraceuticals; lysozyme; Inflammatory Bowel Disease; Crohn’s disease; 46 
Ulcerative Colitis; Mastiha (Pistacia lentiscus)  47 
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INTRODUCTION  49 
Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal disease including 50 
Crohn’s Disease (CD) and Ulcerative Colitis (UC), which has turned into a global 51 
disease (Ng et al., 2017). Lack of adherence to therapeutic regimens, suboptimal 52 
treatment and serious side effects, increased the research interest in natural nutritional 53 
supplements rich in phytochemicals with antioxidant and anti-inflammatory properties 54 
that could be used for maintenance and recovery of intestinal functions.  55 
Many natural products might be ineffective, since the necessity for the manufacturer to 56 
prove efficacy, safety and quality of a marketed product is less strongly enforced than in 57 
the pharmaceutical sector due to lack of rigorous regulation (Andrew & Izzo, 2017; Izzo 58 
et al., 2016; Hunter and Hegele, 2017). Therefore, the research upon the efficacy of 59 
natural products must be based on mechanistic investigation and formal clinical 60 
research studies (Minuz et al., 2017). 61 
Mastic or Mastiha is the dried resinous exudate from stems and branches of Pistacia 62 
lentiscus (Pistacia lentiscus L. var latifolius Coss or Pistacia lentiscus var. Chia) 63 
according to Eur. Ph. Monograph (01/2008:1876). It is rich in terpenic acids with its 64 
main triterpenic acids, mastihadienonic and isomastihadienonic, being absorbed and 65 
bioavailable in humans (Assimopoulou & Papageorgiou, 2005; Paraschos et al., 2007; 66 
Papada et al., 2018). Additionally, it contains arabino-galactanes proteins (AGPs) 67 
(Kottakis et al., 2009), and some simple phenols have also been detected, however in 68 
low concentrations or even in traces (Kaliora et al., 2004). Ancient Greek physicians 69 
(Hippocrates, Dioscorides, Galenos) reported for first time the properties of Mastiha and 70 
recommended its use for its therapeutic properties. Medical practitioners and botanists 71 
used Mastiha for more than 2500 years mainly for the treatment of stomach and 72 
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intestine disorders like gastralgia, dyspepsia and peptic ulcer. Previous studies have 73 
documented its antioxidant (Dedoussis et al., 2004) and anti-inflammatory properties 74 
(Heo et al., 2006), in addition to its beneficial effects on the gastrointestinal system. 75 
More specifically, in patients with gastric ulcers, who were supplemented only with 76 
Mastiha at a dose of 2 g/day, symptoms resolved, while the treatment was confirmed 77 
endoscopically (Huwez et al, 1986). Furthermore, Dabos and colleagues, (2010), 78 
showed that Mastiha is effective in improving symptoms of functional dyspepsia. A 79 
pilot study of safety on patients with established mild to moderately active CD 80 
suggested that a 4-week treatment with Mastiha not only was safe, but also significantly 81 
decreased the activity index, IL-6 and CRP plasma levels. Additionally, Mastiha might 82 
act as an immunomodulator on peripheral blood mononuclear cells, by inhibiting tumor 83 
necrosis factor-alpha and stimulating macrophage migration inhibitory factor (Kaliora et 84 
al., 2007a; 2007b). 85 
The European Medicines Agency has recognised Mastiha as a herbal medicinal product 86 
with the following indications, a) mild dyspeptic disorders, and b) symptomatic 87 
treatment of minor inflammations of the skin and as an aid in healing of minor wounds 88 
(EMA, 2015). 89 
This study is based on the necessity for novel treatments for IBD without serious side 90 
effects, the increasing interest in natural products with favorable effects on health and 91 
disease, and on previous research in Mastiha. Thus, we aimed at demonstrating the 92 
effectiveness of this supplement in quality of life, clinical course and inflammatory 93 
biomarkers of patients in mild to moderate relapse adjunct to current pharmacological 94 
IBD treatments. 95 
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METHODS  96 
 97 
Ethics and trial registration 98 
The study protocol was reviewed and approved by the Harokopio University Ethics 99 
Committee (49/29-10-2015) and it was conducted according to the principles of the 100 
Declaration of Helsinki of 1975 as reflected in the approval by the Harokopio 101 
University Ethics Committee. Laboratory techniques were standardised and the staff of 102 
the study was trained according to Good Clinical Practice. The trial was registered with 103 
ClinicalTrials.gov where the full trial protocol can be accessed (Identifier: 104 
NCT02796339). 105 
 106 
Participants 107 
Enrolment was stimulated through announcement to the Hellenic Society of CD and UC 108 
patients. Confirmed IBD patients, with endoscopy proven UC or CD were enrolled 109 
based on certain inclusion and exclusion criteria (Table 1). They were provided with 110 
detailed information regarding the aims, methods, anticipated benefits and potential 111 
hazards of the study and all patients received the Patient Information Leaflet. Each 112 
patient agreeing to participate provided written Informed Consent and a copy of the 113 
signed Informed Consent form was given to the participant. Patients were recruited 114 
between May 2016 and June 2017. Follow-up visits were completed on September 115 
2017. The study took place in Athens, Greece. 116 
 117 
Study design 118 
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This is a randomised, double-blind, placebo-controlled, parallel group clinical trial 119 
(Figure 1). IBD patients were diagnosed in relapse (moderate disease) as scored by 120 
Harvey Bradshaw Index (HBI) ≥5 and ≤16, and Partial Mayo Score (PMS) ≥2 and ≤6 121 
by experienced gastroenterologists. Since access to the patients full list was unavailable 122 
due to privacy policy of the Society, simple randomisation was applied. After obtaining 123 
the patient's consent, the contact who was independent of the recruitment process would 124 
allocate participants to intervention (verum or placebo). Randomisation was by a 125 
computer generated random number list prepared by an investigator with no clinical 126 
involvement in the trial. Blinding was strictly maintained to intervention staff and 127 
participants. Except for the intervention staff, investigators and analysts were kept blind 128 
to intervention assignment of the participants. Staffs who obtained outcome 129 
measurements were not informed of the intervention group assignment. The Mastiha 130 
group received natural Mastiha supplement at a dose of 2.8 g daily (4 tabs x 700mg 131 
Mastiha), while the placebo group received identical placebo tablets. This dose was 132 
chosen based on a recently published bioavailability study on healthy men, where an 133 
acute dose of 10g of Mastiha was well tolerated and no side effects were observed 134 
(Papada et al, 2018). Preclinical data in TNBS colitic mice showed effectiveness in a 135 
daily dose of 100mg/Kg body weight (Gioxari et al., 2011). Most importantly, a pilot 136 
study of Kaliora et al (2007a 2007b) on patients with mild to moderate activity Crohn’s 137 
disease has served to identify and address any health and safety issues in Mastiha 138 
supplementation in a daily dose above 2 g. No side effects or any discomfort was 139 
reported. The intervention lasted 3 months. Both groups continued their usual medical 140 
treatment, which had to remain unaltered throughout the trial. Additionally, all patients 141 
received standard nutritional advice from dieticians and were encouraged to report any 142 
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adverse effects experienced during the intervention. The verum tablets weighed 0.98 143 
g/tablet and consisted of 70% Mastiha, 14% microcrystalline cellulose, 14% dibasic 144 
calcium phosphate anhydrous and 2% magnesium stearate. The resin was powdered 145 
prior to inclusion in tablet and the powder obtained was off-white to yellowish. 146 
Similarly, the placebo tablets weighed 0.99 g/tablet and consisted of 49% 147 
microcrystalline cellulose with a characteristic off-white to yellowish colour for 148 
similarity to verum, 49% dibasic calcium phosphate anhydrous, and 2% magnesium 149 
stearate. The verum and placebo tablets shared identical appearance and organoleptic 150 
characteristics. Standardisation of the tablets was successful by using crude Mastiha 151 
from the crop of a particular year. Chios Mastiha Growers Association is operating 152 
under a GMP process in its facilities, and has been granted a manufacturer's license by 153 
the Natiοnal Organization for Medicines (EOF). Additionally, it is certified under the 154 
standards of ISO 9001:2008 for the elaboration, packaging and trade of Mastiha, and 155 
ISO 22000:2005, for the elaboration and packaging of Mastiha. In studies using the 156 
present formulation, no natural impurities and related substances have been found in 157 
Mastiha above 0.5 %. 158 
 159 
Baseline assessment 160 
Quality of life assessment: Quality of life was assessed with the validated Inflammatory 161 
Bowel Disease Questionnaire (IBDQ). The IBDQ consists of 32 questions about bowel, 162 
social, systemic and emotional performance and is scored from 32 to 224 points. Higher 163 
scoring indicates a better quality of life (Guyatt et al., 1989). 164 
Medical history: A medical history was recorded by a gastroenterologist, including 165 
general information (i.e. allergic reactions, smoking habits, etc.) as well as specific data 166 
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regarding IBD (i.e. brief history of IBD, age of diagnosis, complications, treatment). 167 
HBI was calculated for CD patients (Harvey & Bradshaw, 1980) and PMS for UC 168 
patients (Lewis et al., 2008). 169 
Blood and stool sample collection: Standard Blood sampling (20mL) was performed. 170 
After collection, blood samples were centrifuged at 3000rpm for 10 minutes at 4◦C for 171 
plasma and serum isolation. All samples were stored at -80◦C until further analysis. 172 
Additionally, patients provided stool samples using a stool preparation system filled 173 
with extraction buffer IDK Extract® (Immundiagnostik, AG). Stool extracts were kept 174 
for a maximum of 9 days at -20◦C until further analysis. 175 
Αnthropometric assessment: Body weight was measured to the nearest 0.1 kg. Height 176 
was measured with a standard stadiometer to the nearest millimeter. Both measurements 177 
were performed twice. Body Mass Index was also calculated.  178 
 179 
Follow-up assessment 180 
There was a biweekly telephone contact with the patients to check upon compliance and 181 
side effects. Compliance to treatments was evaluated by asking the patients to return a 182 
monthly diary completing the daily consumption of tablets. At the end of the 183 
intervention, all parameters of baseline assessment were re-evaluated. 184 
 185 
Laboratory analyses 186 
Evaluation of inflammation: IL-6 (R&D Systems, Inc.) and IL-10 (OriGene 187 
Technologies, Inc.) were assessed applying sandwich ELISA at baseline and at follow-188 
up. Additionally C-Reactive Protein (CRP) was measured in serum. Calprotectin, 189 
lysozyme and lactoferrin were quantified in stool samples (Immundiagnostik, AG).  190 
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 191 
Biochemical analyses: Iron (Fe), Albumin, and plasma Fibrinogen were quantified with 192 
an automatic biochemical analyzer at baseline and at follow-up. Routine laboratory tests 193 
included Lactate Dehydrogenase (LDH), serum urea measured to assess kidney safety, 194 
Serum Glutamic-Oxaloacetic Transaminase (SGOT), Serum Glutamic-Pyruvic 195 
Transaminase (SGPT), γ-Glutamyl Transferase (γ-GT), Alkaline Phospatase (ALP) and 196 
Total & Direct Bilirubin measured to assess liver safety. Serum amylase was measured 197 
to predict any pancreatic disorders. 198 
 199 
Sample size determination and statistical analysis  200 
Sample size calculation was based on the findings of Irvine et al (2000). A sample size 201 
of 58 subjects, 29 per arm, is sufficient to detect a clinically important difference of 202 
28.3 between groups in IBDQ score assuming a standard deviation of 37.3 using a two-203 
tailed t-test of difference between means with 80% power and a 5% level of 204 
significance. Considering a dropout rate of 10% the sample size required is 64 (32 per 205 
group). 206 
Our primary outcome was a clinically significant improvement (namely an increase), in 207 
quality of life as assessed with IBDQ at baseline and after intervention in both arms. 208 
Secondary outcomes included improvement in faecal and serum inflammatory markers 209 
as assessed with the measurement of faecal lysozyme, calprotectin and lactoferrin and 210 
serum IL-6, IL-10 and CRP at baseline and follow-up. Additionally, an improvement of 211 
disease severity reflected by a reduction in HBI and PMS was another secondary 212 
outcome. Improvement in biochemical indices associated with nutritional state (i.e. 213 
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serum Fe, albumin) or acute phase reactants (i.e. plasma fibrinogen) were set as 214 
secondary outcomes. 215 
Continuous variables are presented with mean and standard deviation (SD). Quantitative 216 
variables are presented with absolute and relative frequencies. All analyses were 217 
conducted on an intention-to-treat basis. For the comparison of proportions, chi-squared 218 
and Fisher’s exact tests were used. For the comparison of means between the control 219 
and intervention group the Student’s t-test was computed. To reduce the bias implicit in 220 
utilizing only complete cases, multiple imputation procedures for the all data were 221 
implemented. Differences in changes of study variables during the follow up period 222 
between the two study groups were evaluated using repeated measurements analysis of 223 
variance (ANOVA). Variables with skewed distribution were log-transformed for the 224 
analysis of variance. All p values reported are two-tailed. Statistical significance was set 225 
at 0.05 and analyses were conducted using SPSS statistical software (version 22.0). 226 
11 
 
RESULTS  227 
Sixty IBD patients (N=60) met our criteria for recruitment. Out of the 60 patients, 27 228 
(45.0%) were randomised to the placebo group and 33 (55.0%) to the verum group, 229 
while 40 (66.7%) of them were diagnosed with CD and 20 (33.3%) with UC. Clinical, 230 
anthropometric and demographic characteristics for all groups are presented in Tables 231 
S1 and S2 (Supplementary material). No significant differences were reported between 232 
groups at baseline regarding the demographics, anthropometrics, clinical, biochemical 233 
and inflammatory markers. No adverse events were reported in either treatment arm. 234 
Table 2 presents quality of life and disease activity indices for the two groups. IBDQ 235 
score improved significantly at follow-up only in the intervention arm (Table 3) 236 
although the mean change was not statistically different between the two groups. 237 
Concerning HBI values, a significant decrease was found only in the Mastiha arm, no 238 
significant difference was reported in mean changes between groups.  239 
Table 3 describes routine biochemical data at baseline and at follow-up for Mastiha and 240 
placebo. Also serum Fe, albumin and fibrinogen are presented. There were no 241 
significant differences at baseline between the two groups. At follow-up, only serum Fe 242 
was found to be significantly different between verum and placebo, with the verum 243 
experiencing increase. The mean change in plasma fibrinogen differed significantly 244 
between the two groups. More specifically, plasma fibrinogen decreased significantly 245 
only in the Mastiha group at follow-up. Additionally, serum Fe increased significantly 246 
only in the verum group at follow-up, while serum glucose decreased significantly.  247 
Table 4 illustrates levels of inflammation markers in serum and in stools for the Mastiha 248 
and placebo groups. The change in faecal lysozyme was significantly different between 249 
the two groups. Even when excluding patients who deviated from the protocol, 250 
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lysozyme levels were found to be significantly different in the Mastiha group after 251 
treatment (p=0.027), the change between the two groups being significant after 252 
treatment (p=0.036). Particularly in UC patients, a significant difference in faecal 253 
lysozyme was reported at follow up between these enrolled into the placebo and verum 254 
groups (p=0.048). More specifically, there was a significant decrease only in the 255 
Mastiha group at follow-up. IL-6 increased in both study groups. Faecal calprotectin 256 
and lactoferrin increased significantly in the placebo group at follow-up, while in the 257 
verum group they remained similar to baseline.  258 
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DISCUSSION  259 
Herein, we investigated the effect of a natural supplement prepared with Mastiha to 260 
influence the clinical course of IBD. There are pre-clinical and clinical data supporting 261 
its administration in IBD (Kaliora et al., 2007a; 2007b; Gioxari et al., 2011), but this is 262 
the first study, to our knowledge, evaluating the effectiveness of Mastiha on the basis of 263 
a Phase-II randomised placebo-controlled clinical trial of both CD and UC patients in 264 
relapse. It is important to mention that no adverse effects were reported strengthening 265 
the safety profile of this natural product and coming into agreement with the results of 266 
other clinical studies that evaluated the effectiveness of Mastiha in duodenal ulcer, 267 
dyspepsia and hypercholesterolaemia with no adverse effects and excellent tolerability 268 
(Al-Habbal et al., 1984; Dabos et ., 2010; Kartalis et al., 2016). 269 
In order to assess our primary outcome, namely improvement in quality of life, we used 270 
the IBDQ, the most widely used and validated tool (Alrubaiy et al., 2015), which is fully 271 
validated in the Greek language as well in the original English (Pallis et al., 2001). 272 
Despite a lack of significant difference in mean changes between the study groups, the 273 
IBDQ improved significantly in the Mastiha group but not in the placebo group. 274 
Although the mean score at follow-up in the verum group did not reach the usual range 275 
of patients in remission (170-190 points), this increase shows that Mastiha 276 
supplementation may improve quality of life in IBD patients in relapse when given as 277 
an adjunct to conventional medical therapy. 278 
When evaluating disease severity, we observed a significant decrease in HBI at follow-279 
up compared with baseline only in the Mastiha group. However, the detected decrease 280 
should be interpreted with caution due to the subjective variables comprising the score 281 
(e.g. intensity of abdominal pain and general well-being). A longer period of treatment 282 
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could possibly induce a further reduction in HBI and a significant mean change between 283 
groups, as well as a reduction in PMS for UC patients. However, the nature of active 284 
IBD with frequent changes in medical treatments with fluctuations in dosages would 285 
jeopardise the compliance with our inclusion and exclusion criteria. 286 
To avoid patient discomfort as well as increased drop-out rate and public health cost 287 
due to repeated endoscopies, we evaluated serum and faecal biomarkers of 288 
inflammation. No significant changes in CRP have been identified. Although, CRP is 289 
widely used in clinical practice in order to assess and monitor disease activity and 290 
response to therapy, however it has a low specificity. Therefore, we evaluated also IL-6, 291 
a cytokine with pro-inflammatory effects, and IL-10, a cytokine with anti-inflammatory 292 
activity. Even if we detected no significant changes in the mean changes between the 293 
two groups, further exploration of the effects of Mastiha on other molecules of the 294 
inflammatory cascade is necessary. However we detected noteworthy regulation in 295 
lysozyme, lactoferrin and calprotectin levels. Previous research suggested that faecal 296 
lysozyme is increased in IBD patients and correlates with disease activity, especially in 297 
colonic IBD (van der Sluys Veer et al., 1998). Our study showed a significant decrease 298 
in the lysozyme levels of the Mastiha group, most importantly it showed a significant 299 
difference in mean change between the two groups. When analyzing lysozyme in UC or 300 
CD individually, significantly lower levels at follow-up for the Mastiha group in UC 301 
patients were reported. Lysozyme, an antimicrobial protein that regulates innate 302 
immune response, is expressed in both entities, CD and UC, mainly in small intestine, 303 
but markedly also in the colon, as shown in both experimental animals (Coulombe et al., 304 
2016) and humans (Rubio, 2011; Fahlgren et al., 2003). Since increased lysozyme 305 
expression is correlated with dysbiosis and with inflammation, herein we could 306 
15 
 
hypothesise that the effect of Mastiha is rather a prebiotic one, and possibly stronger in 307 
UC patients, related to the contained phenolic compounds and arabinogalactanes, both 308 
reported to have prebiotic activities (Williamson et al., 2017; Dion et al., 2016). In 309 
addition, faecal calprotectin, a protein present in granulocytes and neutrophils, is 310 
released into the intestinal lumen after leucocyte epithelial migration into the inflamed 311 
gut mucosa and has good diagnostic accuracy in assessing mucosal healing in IBD 312 
patients. Furthermore, faecal lactoferrin is usually elevated in patients with active IBD 313 
detecting inflammation and correlates well with mucosal healing and histological 314 
improvement (Kochhar et al., 2017). In our study, levels of calprotectin and lactoferrin 315 
significantly increased in the placebo but not in the Mastiha group. Significantly lower 316 
levels of lactoferrin at follow-up were found in UC patients under Mastiha treatment. 317 
Regarding biochemical markers, fibrinogen is an acute phase reactant participating in 318 
thrombi formation and its levels increase in inflammatory conditions. Increased 319 
fibrinogen levels are related with higher plasma viscosity and platelet activation, 320 
additionally to the microcirculation of the inflamed intestine (Hudson et al., 1996). 321 
Higher levels of fibrinogen have been detected previously in IBD patients and 322 
increasing levels were associated with disease activity (Dolapcioglu et al., 2014). In our 323 
study, plasma fibrinogen levels decreased significantly in the Mastiha group compared 324 
with baseline, notably the change in mean values between the two groups remained 325 
significant as well. A significant decrease of fibrinogen in the Mastiha group at follow 326 
up (250.2±57.4 mg/dl) compared with baseline (288.3±65.5 mg/dl, p= 0.022) was 327 
reported in CD but not in UC patients. These findings come into agreement with a study 328 
investigating the antidiabetic effects of two pentacyclic triterpenic acids, madecassid 329 
acid and rotundic acid, on a mouse model. Apart from beneficial effects on oxidative 330 
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and inflammatory stress, madecassic acid induced a significant reduction in fibrinogen 331 
levels and plasminogen activator inhibitor (Hsu et al., 2015). Furthermore, another 332 
protocol on a mouse model of diabetes showed that the triterpenoids asiatic and 333 
maslinic acids, act as anti-coagulants, by lowering fibrinogen levels among others 334 
(Hung et al., 2015). Even though these results refer to mouse models and should not be 335 
directly extrapolated to humans, we could hypothesise that terpenes in Mastiha possibly 336 
exhibit favorable effects on homeostatic imbalance of IBD patients.  337 
Serum Fe levels significantly increased in the Mastiha group compared with baseline 338 
and compared with the follow-up levels in the placebo group. Additionally, serum Fe 339 
levels increased significantly in the Mastiha group at follow up (75.3±32.2 μg/dl) 340 
compared with baseline (61.3±30.7 μg/dl, p=0.034) in CD but not in UC patients. Even 341 
though this increase could be partially attributed to increased food intake due to 342 
symptoms improvement, better nutrient absorption or less intestinal losses, this finding 343 
should be interpreted with caution, since several nutrients may fluctuate in serum as 344 
positive or negative acute phase reactants as a part of inflammatory response (Forbes et 345 
al., 2017). 346 
The above findings could also point toward anti-inflammatory properties of the Mastiha 347 
terpenes which have been shown to be absorbed and bioavailable in the systemic 348 
circulation in healthy humans (Papada et al., 2018). 349 
While this study reports interesting findings, it has some limitations, such as the 350 
absence of endoscopy at follow-up, precluding our ability to comment on any 351 
histological alterations. On the other hand, this limitation was compensated by the very 352 
tight control of the verum and placebo groups to ensure compliance of patients with the 353 
protocol, as well as the adequate number of participants that allowed for a power of 0.90 354 
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for the between-subjects main effect at an effect size of 0.37; a power of 0.95 for the 355 
within-subjects main effect at an effect size of 0.25; and a power of 0.95 for the 356 
interaction effect at an effect size of 0.25. Nevertheless, larger-scale clinical trials are 357 
essential to determine the effect of terpene-rich Mastiha in the health of patients with 358 
IBD and its potential underlying mechanisms. 359 
 360 
Conclusive remarks 361 
Since there is an increasing usage of natural products among IBD patients, our study 362 
aimed at investigating the effects of Mastiha in quality of life, disease activity, and 363 
biochemical and faecal inflammatory markers. Our results showed for the first time that 364 
a natural supplement prepared with Mastiha could serve as an innovative treatment 365 
approach as an adjunct to conventional medical therapy. Mechanistically, regulation of 366 
faecal lysozyme secondary to a prebiotic effect is proposed. 367 
 368 
369 
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TABLE 1. Inclusion and exclusion criteria  515 
Inclusion criteria Exclusion criteria 
Sex: Male and Female Positive stool culture for enteric pathogens 
or Clostridium difficile toxin 
Age: 18-67 years old Antibiotic treatment during and 2 months 
prior to screening 
IBD established by endoscopy, with 
consistent histology and clinical course 
Bowel surgery ≤3 months prior to 
screening; a planned elective surgery or 
hospitalisation during the study; clinically 
significant short bowel syndrome; presence 
of an intra-abdominal abscess or a fistula 
with clinical or radiological evidence of an 
associated abscess; ileostomy; colostomy 
Active disease (moderate) 
- defined by 5 ≤ HBI ≤ 16 in CD,  
- defined by 2 ≤ PMS ≤ 6 in UC  
Enteral or Parenteral Nutrition; alcohol or 
drug abuse, vitamin or inorganic 
supplements, vegan or macrobiotic diet 
before and during the trial 
Stable treatment with steroids for at 
least 2 weeks before the start of the 
trial, mesalamine and mesalamine 
analogues for 4 weeks and 
immunosuppressants for 8 weeks  
Any malignancy in the year prior to 
screening; cardiovascular disease; peptic 
ulcer 
Stable medication during the trial Pregnancy, lactation 
 516 
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TABLE 2. Quality of life and disease activity indices at baseline and follow up. 517 
  Baseline Follow-up Change     
  Mean (SD) Mean (SD) Mean (SD) P1 P2 
IBDQ score           
Placebo  144.9 (29.0) 155.1 (33.3) 10.2 (43.6) 0.137 0.380 
Mastiha  145.2 (27.3) 163.4 (30.6) 18.3 (26.4) 0.004 
 
P3 0.975 0.319 
   
HBI+            
Placebo  6.1 (1.8) 4.7 (2.6) -1.4 (2.6) 0.055‡ 0.635‡ 
Mastiha  7.8 (2.3) 4.7 (3.8) -3.1 (4.1) <0.001‡ 
 
P3 0.134‡ 0.691‡ 
   
PMS++           
Placebo  3.2 (2.0) 2.2 (1.6) -1.0 (2.1) 0.055 0.324 
Mastiha  2.8 (1.8) 2.0 (1.3) -0.9 (2.0) 0.481 
 
P3 0.114 0.355 
   
1p-value for time effect; 2Effects reported include differences between the groups in 518 
mean changes (repeated measurements ANOVA); 3p-value for group effect; ‡based on 519 
logarithmic transformations; + only in patients with CD; ++only in patients with UC520 
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TABLE 3. Biochemical data at baseline and at follow up. 521 
  Baseline Follow-up Change     
  Mean (SD) Mean (SD) Mean (SD) P1 P2 
Plasma fibrinogen (mg/dL)        
Placebo  288.1 (66.9) 276.7 (83.2) -11.4 (83.7) 0.441 0.018 
Mastiha  281.5 (58.1) 243.3 (54.4) -38.3 (69.9) 0.006 
 
P3 0.687 0.067 
   
Serum Fe (μg/dL)         
Placebo  53.9 (27.0) 56.9 (24.0) 3.0 (24.7) 0.614 0.278 
Mastiha  61.1 (30.5) 72.8 (29.2) 11.7 (34.9) 0.032 
 
P3 0.343 0.027 
   
Serum albumin (g/dL)         
Placebo  4.3 (0.3) 4.2 (0.6) -0.1 (0.5) 0.364 0.427 
Mastiha  4.3 (0.4) 4.3 (0.5) 0.0 (0.6) 0.858 
 
P3 0.474 0.764 
   
Serum amylase (IU/L)         
Placebo  68.2 (23.0) 68.8 (23.5) 0.6 (21.1) 0.871 0.577 
Mastiha  67.6 (20.3) 65.3 (20.7) -2.2 (17.8) 0.514 
 
P3 0.909 0.546 
   
Serum urea (mg/dL)         
Placebo  29.9 (7.7) 28.2 (6.9) -1.8 (6.3) 0.238‡ 0.797‡ 
Mastiha  31.9 (10.1) 29.0 (7.2) -2.9 (8.7) 0.094‡ 
 
P3 0.504‡ 0.621‡ 
   
Serum LDH (U/L)        
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Placebo  154.8 (41.1) 188 (66) 33.2 (65.6) 0.006‡ 0.975‡ 
Mastiha  143.9 (30.9) 183.5 (119.7) 39.5 (117.9) 0.003‡ 
 
P3 0.284‡ 0.421‡ 
   
Serum total bilirubin (mg/dL)        
Placebo  0.32 (0.24) 0.48 (0.45) 0.15 (0.52) 0.275‡ 0.361‡ 
Mastiha  0.43 (0.41) 0.55 (0.71) 0.12 (0.71) 0.877‡ 
 
P3 0.221‡ 0.899‡ 
   
Serum direct bilirubin (mg/dL)       
Placebo  0.15 (0.12) 0.19 (0.13) 0.04 (0.15) 0.050‡ 0.001‡ 
Mastiha  0.23 (0.17) 0.15 (0.15) -0.08 (0.21) 0.003‡ 
 
P3 0.281‡ 0.251‡ 
   
Serum SGOT (IU/L)         
Placebo  17.5 (9.3) 18.5 (8.6) 0.9 (12.8) 0.381‡ 0.095‡ 
Mastiha  14.8 (4.8) 19.3 (7.0) 4.5 (6.7) 0.001‡ 
 
P3 0.182‡ 0.414‡ 
   
Serum SGPT (IU/L)         
Placebo  18.3 (12.5) 15.3 (7.7) -3.1 (9.4) 0.208‡ 0.810‡ 
Mastiha  18.9 (10.3) 17.4 (8.6) -1.6 (7.6) 0.299‡ 
 
P3 0.519‡ 0.317‡ 
   
Serum γ-GT (IU/L)          
Placebo  19.2 (11.6) 18.2 (8.9) -0.9 (9.9) 0.942‡ 0.221‡ 
Mastiha  21.4 (13.3) 17.1 (6.2) -4.3 (10.5) 0.059‡ 
 
P3 0.330‡ 0.921‡ 
   
Serum ALP (IU/L)      
29 
 
Placebo  64 (17.8) 65.6 (15.8) 1.6 (9.4) 0.550 0.107 
Mastiha  68.3 (21.4) 64 (16.9) -4.2 (16.4) 0.081 
 
P3 0.408 0.720 
   
1p-value for time effect; 2Effects reported include differences between the groups in 522 
mean changes (repeated measurements ANOVA); 3p-value for group effect; ‡based on 523 
logarithmic transformations 524 
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TABLE 4. Serum and faecal inflammatory markers at baseline and at follow up.  525 
 
Baseline Follow-up Change     
 
Mean (SD) Mean (SD) Mean (SD) P1 P2 
Serum CRP (mg/L) 
Placebo  6.4 (7.6) 5.3 (4.8) -1.1 (8.0) 0.767‡ 0.791‡ 
Mastiha  6.9 (8.2) 5.7 (5.9) -1.2 (8.3) 0.946‡ 
 
P3 0.616‡ 0.788‡ 
   
Serum IL-6 (pg/mL) 
Placebo  14.4 (16.8) 24.3 (43.8) 9.9 (33.6) 0.030 0.955 
Mastiha  11.5 (12.3) 15.7 (13.3) 4.2 (9.7) 0.021 
 
P3 0.552 0.502 
   
Serum IL-10 (pg/mL)          
Placebo  8.8 (18.9) 9.5 (20.1) 0.6 (3.4) 0.454 0.607 
Mastiha  6.1 (2.7) 6.1 (2.7) 0.0 (3.6) 0.951 
 
P3 0.920 0.713 
   
Faecal lysozyme (μg/g) 
Placebo  11.7 (10.6) 15.6 (15.8) 3.9 (18.2) 0.326 0.021 
Mastiha  18.8 (21.2) 10.3 (5.2) -8.4 (21.8) 0.018  
P3 0.075 0.208    
Faecal calprotectin (μg/g) 
Placebo  2170.6 (4444.4) 3598.5 (3620.4) 1427.9 (5606.1) 0.029 0.348 
Mastiha  1688.6 (1712.4) 2744 (4910.6) 1055.4 (5043.1) 0.289  
P3 0.825 0.357    
Faecal lactoferrin (μg/g) 
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Placebo  102.4 (128.7) 306.3 (373.7) 203.9 (376.4) 0.001 0.130 
Mastiha  130.4 (140.2) 165.6 (150.8) 35.2 (179.9) 0.109  
P3 0.479 0.240    
1p-value for time effect (based on logarithmic transformations); 2Effects reported 526 
include differences between the groups in mean changes (repeated measurements 527 
ANOVA) (based on logarithmic transformations); 3p-value for group effect (based on 528 
logarithmic transformation).  529 
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Figure legends 530 
Figure 1. Study design flowchart 531 
